Cidara Therapeutics Inc.

0.6350+0.0050+0.79%Vol 416.58K1Y Perf -61.59%
Aug 12th, 2022 16:00 DELAYED
BID0.6000 ASK0.6480
Open0.6306 Previous Close0.6300
Pre-Market- After-Market0.64
 - -  0.00 0.16%
Target Price
5.65 
Analyst Rating
Strong Buy 1.00
Potential %
789.76 
Finscreener Ranking
     40.10
Insiders Trans % 3/6/12 mo.
-/-100/67 
Value Ranking
     32.23
Insiders Value % 3/6/12 mo.
-/-100/100 
Growth Ranking
     34.30
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/99 
Income Ranking
 —    -
Price Range Ratio 52W %
11.81 
Earnings Rating
Sell
Market Cap44.50M 
Earnings Date
11th Aug 2022
Alpha-0.04 Standard Deviation0.19
Beta1.23 

Today's Price Range

0.59400.6466

52W Range

0.40002.39

5 Year PE Ratio Range

-1.70-1.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-9.30%
1 Month
-17.53%
3 Months
48.36%
6 Months
-21.12%
1 Year
-61.59%
3 Years
-51.53%
5 Years
-89.67%
10 Years
-

TickerPriceChg.Chg.%
CDTX0.63500.00500.79
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
-
-77.90
-77.90
-
-80.98
RevenueValueIndustryS&P 500US Markets
21.41M
0.31
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.28-0.1932.14
Q01 2022-0.26-0.27-3.85
Q04 2021-0.33-0.2621.21
Q03 2021-0.37-0.370.00
Q02 2021-0.270.18166.67
Q01 2021-0.17-0.39-129.41
Q04 2020-0.14-0.49-250.00
Q03 2020-0.48-0.4114.58
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.28-3.70Negative
9/2022 QR-0.27-3.85Negative
12/2022 FY-1.11-11.00Negative
12/2023 FY-0.90-18.42Negative
Next Report Date-
Estimated EPS Next Report-0.28
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume416.58K
Shares Outstanding70.08K
Shares Float67.97M
Trades Count943
Dollar Volume257.66K
Avg. Volume618.67K
Avg. Weekly Volume479.66K
Avg. Monthly Volume832.33K
Avg. Quarterly Volume544.02K

Cidara Therapeutics Inc. (NASDAQ: CDTX) stock closed at 0.635 per share at the end of the most recent trading day (a 0.79% change compared to the prior day closing price) with a volume of 416.58K shares and market capitalization of 44.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Cidara Therapeutics Inc. CEO is Jeffrey Stein.

The one-year performance of Cidara Therapeutics Inc. stock is -61.59%, while year-to-date (YTD) performance is -50%. CDTX stock has a five-year performance of -89.67%. Its 52-week range is between 0.4 and 2.39, which gives CDTX stock a 52-week price range ratio of 11.81%

Cidara Therapeutics Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 8.91, a price-to-sale (PS) ratio of 2.06, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -79.74%, a ROC of -467.58% and a ROE of -1 259.15%. The company’s profit margin is -80.98%, its EBITDA margin is -77.90%, and its revenue ttm is $21.41 Million , which makes it $0.31 revenue per share.

Of the last four earnings reports from Cidara Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Cidara Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cidara Therapeutics Inc. is Strong Buy (1), with a target price of $5.65, which is +789.76% compared to the current price. The earnings rating for Cidara Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cidara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cidara Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.60, ATR14 : 0.07, CCI20 : -109.14, Chaikin Money Flow : -0.39, MACD : 0.01, Money Flow Index : 71.39, ROC : -16.66, RSI : 51.31, STOCH (14,3) : 17.67, STOCH RSI : 0.06, UO : 48.48, Williams %R : -82.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cidara Therapeutics Inc. in the last 12-months were: Brady Johnson (Sold 654 shares of value $530 ), Jeffrey Stein (Buy at a value of $166 285), Preetam Shah (Buy at a value of $30 800), Timothy R. Franson (Buy at a value of $14 823)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cidara Therapeutics Inc.

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's main drug constitutes echinocandins antifungals in the form of CD101IV and CD101 topical. It has developed a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious diseases.

CEO: Jeffrey Stein

Telephone: +1 858 752-6170

Address: 6310 Nancy Ridge Drive, San Diego 92121, CA, US

Number of employees: 68

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

Bearish Bullish

56%44%


News

Stocktwits